Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
BURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the third quarter ended September 30, 2023.
The Company continues to work with the U.S. Food and Drug Administration (FDA) during its review of its New Drug Application (NDA) for roluperidone for the treatment of negative symptoms of schizophrenia, in advance of the February 26, 2024 PDUFA date.
"We remain committed to bringing roluperidone to patients and physicians as we believe it addresses a significant unmet clinical need and has the potential to improve patients' quality of life and expand treatment options available to physicians. If approved, roluperidone would be the first medication for negative symptoms of schizophrenia to receive regulatory approval," said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva.
Third Quarter 2023 Financial Results
- Research and development (R&D) expense: For the three months ended September 30, 2023 and 2022, R&D expense was $3.4 million and $2.4 million, respectively. R&D expense was higher versus the prior year primarily due to costs associated with the FDA's review of the Company's NDA. For the nine months ended September 30, 2023 and 2022, R&D expense was $8.0 million and $11.5 million, respectively. The decrease in R&D expense versus the prior year was primarily due to higher costs in 2022 related to the preparation of the NDA for roluperidone, which was submitted in August 2022.
- General and administrative (G&A) expense: For the three months ended September 30, 2023 and 2022, G&A expense was $2.6 million and $2.8 million, respectively. For the nine months ended September 30, 2023 and 2022, G&A expense was $8.0 million and $8.7 million, respectively. The decrease in G&A expense for the three and nine-months ended September 30, 2023 versus the prior year was primarily due to lower non-cash stock compensation costs.
- Non-cash interest expense: For the three months ended September 30, 2023 and 2022, non-cash interest expense for the sale of future royalties was $2.1 million and $1.9 million, respectively. For the nine months ended September 30, 2023 and 2022, non-cash interest expense was $6.1 million and $5.5 million, respectively. The Company amortizes non-cash interest expense for the difference between the balance of the liability related to the sale of future royalties and the estimated amount future royalties to be received over the royalty period.
- Net loss: Net loss was $7.8 million for the three months ended September 30, 2023, or net loss per share of $1.03 basic and diluted, as compared to net loss of $6.9 million, or net loss per share of $1.29 basic and diluted, for the three months ended September 30, 2022. Net loss was $21.0 million for the nine months ended September 30, 2023, or net loss per share of $3.41 basic and diluted, as compared to net loss of $25.4 million, or net loss per share of $4.75 basic and diluted for the nine months ended September 30, 2022.
- Cash Position: Cash, cash equivalents and restricted cash at September 30, 2023, were approximately $47.0 million, as compared to $36.2 million at December 31, 2022.
About Minerva Neurosciences
Minerva Neurosciences, Inc. (NASDAQ:NERV) is a clinical-stage biopharmaceutical company focused on developing product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options. Minerva's portfolio of compounds includes roluperidone (f/k/a MIN-101), for negative symptoms of schizophrenia, and MIN-301, for Parkinson's disease. For more information, please visit our website.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include, but are not limited to, statements herein with respect to the regulatory progress and therapeutic potential of roluperidone for the treatment of negative symptoms in patients with schizophrenia. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether the FDA will require additional trials or data which may significantly delay and put at risk our efforts to obtain regulatory approval; whether the FDA may meet expected review timelines for our NDA; whether roluperidone will be successfully marketed if approved; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations and corporate objectives on terms acceptable to us; general economic conditions; and other factors that are described under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 8, 2023, as updated by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. Copies of reports filed with the SEC are posted on our website at http://ir.minervaneurosciences.com/. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.
Contact:
Investor inquiries:
Frederick Ahlholm
Chief Financial Officer
Minerva Neurosciences, Inc.
[email protected]
Media inquiries:
Helen Shik
Principal
Shik Communications LLC
[email protected]
| CONDENSED CONSOLIDATED BALANCE SHEET DATA | ||||||
| (Unaudited) | ||||||
| September 30, 2023 | December 31, 2022 | |||||
| (in thousands) | ||||||
| ASSETS | ||||||
| Current Assets: | ||||||
| Cash and cash equivalents | $ | 46,904 | $ | 36,094 | ||
| Restricted cash | 100 | 100 | ||||
| Refundable regulatory fee | - | 3,117 | ||||
| Prepaid expenses and other current assets | 1,221 | 848 | ||||
| Total current assets | 48,225 | 40,159 | ||||
| Equipment & capitalized software, net | 36 | 59 | ||||
| Goodwill | 14,869 | 14,869 | ||||
| Total Assets | $ | 63,130 | $ | 55,087 | ||
| LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY | ||||||
| Current Liabilities: | ||||||
| Accounts payable | $ | 1,395 | $ | 969 | ||
| Accrued expenses and other current liabilities | 1,955 | 408 | ||||
| Total current liabilities | 3,350 | 1,377 | ||||
| Long-Term Liabilities: | ||||||
| Liability related to the sale of future royalties | 79,826 | 73,734 | ||||
| Total liabilities | 83,176 | 75,111 | ||||
| Stockholders' (Deficit) Equity: | ||||||
| Common stock | 1 | 1 | ||||
| Additional paid-in capital | 367,746 | 346,785 | ||||
| Accumulated deficit | (387,793 | ) | (366,810 | ) | ||
| Total stockholders' (deficit) equity | (20,046 | ) | (20,024 | ) | ||
| Total Liabilities and Stockholders' (Deficit) Equity | $ | 63,130 | $ | 55,087 | ||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||
| (Unaudited) | ||||||||||||||
| Three Months Ended September 30, (in thousands, except per share amounts) | Nine Months Ended September 30 (in thousands, except per share amounts) | |||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||
| Operating expenses: | ||||||||||||||
| Research and development | $ | 3,444 | $ | 2,367 | $ | 7,985 | $ | 11,459 | ||||||
| General and administrative | 2,635 | 2,840 | 7,963 | 8,703 | ||||||||||
| Total operating expenses | 6,079 | 5,207 | 15,948 | 20,162 | ||||||||||
| Loss from operations | (6,079 | ) | (5,207 | ) | (15,948 | ) | (20,162 | ) | ||||||
| Foreign exchange (losses) gains | (5 | ) | 2 | (21 | ) | - | ||||||||
| Investment income | 349 | 180 | 1,079 | 260 | ||||||||||
| Non-cash interest expense for the sale of future royalties | (2,085 | ) | (1,875 | ) | (6,093 | ) | (5,481 | ) | ||||||
| Net loss | $ | (7,820 | ) | $ | (6,900 | ) | $ | (20,983 | ) | $ | (25,383 | ) | ||
| Net loss per share, basic and diluted | $ | (1.03 | ) | $ | (1.29 | ) | $ | (3.41 | ) | $ | (4.75 | ) | ||
| Weighted average shares outstanding, basic and diluted | 7,569 | 5,340 | 6,148 | 5,340 | ||||||||||
